GliaCure News

GliaCure President Phil Haydon was co-author of a paper published in the Proceedings of the National Academy of Sciences (Tang-Schomer et al, 2014) and featured recently in the New York Times (August 11, 2014). This paper described the creation and potential uses of synthetic 3-D brain-like tissue. This tissue, composed of a modular design of…more »

B round financing with new and existing investors will advance GliaCure’s Alzheimer’s clinical program GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, today announced that it has successfully completed a $5.8 million B round financing, exceeding its original goal of $5 million. This financing round…more »

Mr. Zakrzewski is a Seasoned Life Sciences Leader GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company’s Board of Directors. Mr. Zakrewski brings more than 20 years of experience to his new role as…more »

GliaCure is pleased to announce that Dr. Rudy Schreiber has joined the team as Vice President of Translational Research and Development. Dr. Schreiber previously held positions at Roche, Sepracor and Evotec, where he developed expertise and leadership in behavioral studies with a specific focus on CNS projects. His experience as a scientist and as a…more »

GliaCure has recently been joined by Alan Barber of the Prestar Group as its CFO. Alan began his career as a CPA with Coopers & Lybrand. As a partner in Coopers Dallas and Tokyo offices his responsibilities included Mergers & Acquisitions Practice Leader for the Southwest Region and Partner-in-Charge of the Foreign Financial Services practice…more »

GliaCure President Phil Haydon’s recent findings on the role of glia in sleep disorders and depression were reported today in the industry publication BioWorld. http://www.bioworld.com/content/support-cells-star-lack-sleeps-antidepressant-effects

During the 2012 BIO International Convention in June GliaCure President Phil Haydon had an interesting conversation with Rob Wright, Chief Editor of Life Science Leader magazine. Phil and Rob talked about how, to be innovative in drug discovery, one often has to ignore established thinking. Based on this conversation, Phil was asked to write an…more »

On Wednesday, October 3 GliaCure President Phil Haydon will be one of four panelists presenting a lunchtime briefing on Capitol Hill titled: “Where Do We Stand With Alzheimer’s Research?” This briefing is intended to give updates on Alzheimer’s research and funding. Phil is participating at the invitation of Massachusetts Congressman Ed Markey’s office. Rep. Markey…more »

GliaCure President Phil Haydon and Vice President Mike Szulczewski will be at the BioPharm America 2012 conference in Boston from September 19 to 21. Phil and Mike will be participating in a range of one-on-one meetings during the conference. Phil Haydon has also been selected to make a Next Generation presentation on Friday, September 21…more »